ImmunoClin News Releases

ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC

BEVERLY HILLS, Calif., July 29, 2014 /PRNewswire/ -- ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders.  As of August 1, 2014, ImmunoClin Corporation will complete the strategic relocation of its corporate headquarters to Washington, D.C., a key center of North American healthcare and biotechnology industries and related governmental agencies. In addition, the Company's chief operating officer, general counsel, and director, Chad S. Johnson, Esq., who will oversee the principal corporate office, is a decades-long D.C. resident.

"We are excited to move ImmunoClin's head office to Washington, D.C.  The location is attractive for obvious regulatory and business reasons, as we continue to progress our strategic growth plan.  Further, under the oversight of officer and director, Chad Johnson, theWashington office will work seamlessly with our established European headquarters in London, United Kingdom and laboratories in central Paris, France," said Dr. Dorothy Bray, Director, President and CEO of ImmunoClin Corporation.

"Washington, D.C. is a great location for the Company's principal office.  ImmunoClin will join the ranks of the expansive tech and healthcare presence in the D.C. area and be positioned to take advantage of the proximity to and interaction with the federal government, including departments and agencies such as HHS, FDA, NIH, USPHS, and USPTO -- not to mention the impressive public and private educational and research institutions located in greater D.C.," said Chad S. Johnson, Esq., Director, COO and General Counsel.  "I am honored to spearhead the efforts of IMCL from our new D.C. office in conjunction with our international board of directors and scientific advisory board."

About ImmunoClin Corporation
ImmunoClin Corporation is a healthcare company with European headquarters in London, United Kingdom and laboratories in central Paris, France -- and principal corporate office being established in Washington, D.C., USA. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease.  ImmunoClin holds multiple patents and trademarks on a global basis.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.

ImmunoClin Corporation
Dr. Dorothy Bray, Director, President & CEO
www.immunoclin.com
This email address is being protected from spambots. You need JavaScript enabled to view it.  
Tel: 1.888.267.1175

Investment Inquiries
J. Scott Munro, CFO 
This email address is being protected from spambots. You need JavaScript enabled to view it.   
Cell: +1 778-987-4308

 

Upcoming Events

April 21-23, 2016 Dubai, United Arab Emirates
6th Global Experts Meeting & Expo on Nanomaterials and Nanotechnology 
Learn More

August 21-26, 2016 Melbourne, Australia
International Congress of Immunology
Learn More

August 22-25, 2016 in Sendai City, Miyagi, Japan
16th International Conference on Nanotechnology: Green Nanotechnology for a Sustainable Society
Learn More

October 3-5, 2016, London, United Kingdom
4th International Conference on Geriatrics & Gerontology
Learn More

October 9-10, 2016 Dubai, United Arab Emirates
International Congress in Aesthetics, Anti-Ageing and Medical
Learn More

October 12-13, 2016, San Francisco, California, USA
8th Annual Personalized &Precision Medicine Conference
Learn More

December, 8-10, 2016, Dubai, United Arab Emirates
7th International Conference on Clinical Nutrition
Learn More

February 15-17, 2017, Tokyo, Japan
International Nanotechnology Exhibition Conference
Learn More

February 16-17, 2017, London, United Kingdom
19th International Conference on Immunology
Learn More

June 21-22, 2017, Vienna, Austria
19th International Conference on Nanotechnology and Nanomedicine
Learn More

July 23-27, 2017, San Francisco, California, USA
International Association of Gerontology and Geriatrics Conference
Learn More

October 22-27, 2017 Buenos Aires, Argentina
21st IUNS-ICN International Congress of Nutrition
Learn More